Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01861145 : Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea
PhasePhase 4
AgesMin: 5 Years Max: 17 Years
Eligibility
Inclusion Criteria:

- Ages between 5-17

- endorse 5/6 questions on the PSQ-22. These questions include: While sleeping, does
your child: Ever snore? Snore more than half the time? Always snore? Snore loudly?
Have "heavy" or loud breathing? Have trouble breathing, or struggle to breath?

- desire to use the bed alarm

Exclusion Criteria:

- Children <5

- known neurological disorders resulting in neuropathic bowel or bladder disorder
including, but not limited to spinal dysraphisms and spinal cord injuries.

- significant congenital bladder anomalies, such as bladder exstrophy or posterior
urethral valves

- patients with craniofacial anomalies or syndromes known to be associated with
obstructive sleep apnea (i.e. Trisomy 21, muccopolysaccardiosis)
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01861145      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740